News
DGAP-News: EVOTEC UND CELMATIX GEHEN STRATEGISCHE ZUSAMMENARBEIT EIN
DGAP-News: EVOTEC AND CELMATIX ENTER INTO STRATEGIC COLLABORATION
Why Summit Therapeutics Rocketed Over 60% Today
Shares of Summit Therapeutics (NASDAQ: SMMT) rocketed as high as 75.2% Monday, before settling into a 57.5% gain as of 1:27 PM EDT.
The biotech firm released the results of a Phase III study on
What's Wrong With Merck's Stock?
Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest
EQS-News: Evotec announces change in Management Board
EQS-News: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
EQS-News: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
You might think that if a drugmaker has a top-selling drug, it would be a lock to be a top-performing stock and a no-brainer buy. That may be true in some cases. In others, it can be a source of
EQS-News: Evotec SE reports H1 2024 results: Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths
EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
EQS-News: Evotec SE reports first half-year 2024 results on 14 August 2024
EQS-News: MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market
EQS-News: MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market
Merck (MRK) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Merck (NYSE: MRK)Q2 2024 Earnings CallJul 30, 2024, 9:00 a.m. ET
Operator
Source Fool.com
EQS-Adhoc: Merck KGaA: Strong 2nd Quarter, Guidance raised
2 Magnificent Stocks to Buy With $500
Some might hesitate to invest in stocks during a bull run, like the one we are experiencing. They argue that equities are likely to be overvalued. However, it's possible to find reasonably valued
EQS-News: MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
EQS-News: MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
EQS-Adhoc: Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
EQS-Adhoc: Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
EQS-News: Evotec and Pfizer collaborate to advance drug discovery in France
EQS-News: Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz